- Advanced search
|International Nonproprietary Names|
|Search PubMed clinical trials||labetuzumab|
|Search PubMed titles||labetuzumab|
|Search PubMed titles/abstracts||labetuzumab|
|Labetuzumab is a humanised mouse monoclonal antibody targeting CEACAM5 (CD66e), a tumour marker that can be measured in serum.
Labetuzumab can be labelled with radioactive isotopes such as yttrium-90 and iodine-131, providing targeted radioimmumotherapy.
Labetuzumab has been used to generate an antibody-drug conjugate (ADC) called labetuzumab govitecan, in which the antibody is covalently bound to SN-38, the active metabolite of the topoisomerase inhibitor, irinotecan.